A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

NCT02167139 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

544

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Humira (adalimumab)
DRUG: SB5 (proposed biosimilar to adalimumab)

Sponsor

Samsung Bioepis Co., Ltd.